ArticlePharmaceuticals (Basel, Switzerland)2025
Study on the Excretion of a New Antihypertensive Drug 221s (2,9) in Rats.
Yunmei Chen, Kuan Yang, Shaojing Liu, Lili Yu, Rong Wang, Bei Qin
Abstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Yunmei ChenXi'an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi'an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi'an Medical University, Xi'an 710021, China.
Kuan YangXi'an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi'an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi'an Medical University, Xi'an 710021, China.
Shaojing LiuXi'an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi'an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi'an Medical University, Xi'an 710021, China.
Lili YuXi'an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi'an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi'an Medical University, Xi'an 710021, China.
Rong WangXi'an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi'an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi'an Medical University, Xi'an 710021, China.
Bei QinXi'an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi'an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi'an Medical University, Xi'an 710021, China.
Funding
the Natural Science Basic Research Program of Shaanxi Provincial Department of Science and Technology 2024JC-YBQN-0956
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
excretionhypertensionUPLC-MS/MS
Identifiers
PMID40872528
PMCPMC12389711
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390